In HER2-enriched BC patients treated with neoadjuvant trastuzumab and chemotherapy, HER2 copy number heterogeneity was shown to impact disease progression and survival, emphasizing the importance of HER2 copy number monitoring to predict the therapy response [31]. This evidence concerns the gene ERBB2 and breast cancer.